title: A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→ 3)-β-d-glucan chromogenic assay in serum samples.
abstract: Diagnosis of fungal pneumonia (FP) in critically ill patients is challenging. Circulating biomarkers for the diagnosis of FP have limitations and the combination of different assays in serum samples and directly from the target organ may further improve the diagnosis of FP. We prospectively assessed the diagnostic utility of paired galactomannan (GM) in bronchoalveolar lavage fluid (BAL) and serum GM and (1→3)-β-D-glucan (BG) assays in critically ill patients at risk of FP. Patients with FP were classified according to European Organisation for Research and Treatment of Cancer-Mycoses Study Group criteria, with modifications. Out of 847 admissions, 51 patients were eligible. There were nine invasive aspergillosis (IA) cases (four proven, five probable), three proven Pneumocysitis jirovecii pneumonia (PJP) cases and one mixed FP case (probable IA and proven PJP). The diagnostic accuracy as given by the area under the receiver operating characteristic curve in IA cases (proven and probable) for GM in BAL was 0.98 (95% CI, 0.94-1.00), whilst for GM and BG in serum it was 0.85 (95% CI, 0.74-0.96) and 0.815 (95% CI, 0.66-0.96), respectively. For IA cases (proven and probable) AUC for GM in BAL was significantly higher than GM and BG in serum (p 0.025 and p 0.032, respectively). In one of four proven and one of six probable IA cases, GM in serum remained negative, whereas GM in BAL was positive. In patients with IA, GM (90%) and BG (80%) appeared a mean of 4.3 days (range, 1-10 days) before Aspergillus was cultured. GM detection in BAL appears to improve the diagnosis of IA in critical patients.
authors.affiliation: Department of Medical Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Acosta
authors.forename: M
authors.initials: M
authors.lastname: Catalan
authors.forename: A
authors.initials: A
authors.lastname: del Palacio-Peréz-Medel
authors.forename: D
authors.initials: D
authors.lastname: Lora
authors.forename: J-C
authors.initials: JC
authors.lastname: Montejo
authors.forename: M-S
authors.initials: MS
authors.lastname: Cuetara
authors.forename: M-D
authors.initials: MD
authors.lastname: Moragues
authors.forename: J
authors.initials: J
authors.lastname: Ponton
authors.forename: A
authors.initials: A
authors.lastname: del Palacio
mesh_terms: D000328:Adult; D000368:Aged; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D003422:Critical Care / Q000379:methods; D016638:Critical Illness; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000175:diagnosis*; D008297:Male; D008351:Mannans / Q000032:analysis* / Q000097:blood; D008875:Middle Aged; D011446:Prospective Studies; D011509:Proteoglycans; D012372:ROC Curve; D044967:Serum / Q000737:chemistry; D047071:beta-Glucans / Q000097:blood
chemical_list: D008351:Mannans; D011509:Proteoglycans; D047071:beta-Glucans; C012990:galactomannan; C010770:polysaccharide-K; D005690:Galactose